Xtandi (enzalutamide) Phase III trial starts today for non-metastatic castrate resistant prostate cancer, including Australia

[JimJimJimJim]

Jim Marshall (not a doctor) said ...

 

A Phase 3 Study of Xtandi (Enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer enrolled its first subject today.

 

Australia is included in the countries where this trial (PROSPER) are offered.

 

We will let you have more information when it is to hand.

 

In the meantime, if you have rising PSA while castrate resistant (low testosterone), ask your doctor about this.

 

Trials of drugs that people expect will be good tend to fill quickly.

... end Jim

 

Click the following line for the press release:

 

Phase 3 Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer